RemediumOne
RemediumOne is a Sri Lanka-based clinical development organization founded in 2009 that delivers end-to-end clinical trial management, medical affairs, and commercialization services to global pharmaceutical companies, CROs, and academic institutions through an 80+ site investigator network across 12+ therapeutic areas.
- Company typePrivate
- Founded2009
- HeadquartersColombo, Sri Lanka
- Headcount51–100
- GTM typeB2B
- OfferingServices
What RemediumOne does
RemediumOne is a privately-held clinical development organization (CRO) headquartered in Colombo, Sri Lanka, founded in 2009 as a spinoff from the Clinical Trials Unit at the University of Kelaniya. The company delivers end-to-end clinical trial management services—including feasibility, site selection, patient recruitment and retention, monitoring, data management, biostatistics, regulatory support, and pharmacovigilance—across 12+ therapeutic areas (cardiovascular, CNS, endocrine/metabolic, gastroenterology, infectious diseases/vaccines, nephrology, oncology, respiratory, ophthalmology) plus cross-functional capabilities in biosimilars and rare diseases. Its core operational asset is a network of 80+ investigator sites and 300+ investigators across Sri Lanka, supported by 100+ GCP-trained full-time staff, the country's only ACRP-qualified clinical trial monitor, and ISO 9001:2015 and ISO 27001:2022 certifications. RemediumOne also offers adjacent service lines in Medical Affairs, Commercialization (market access, pricing, HEOR), and Consulting, and has launched decentralized clinical trial capabilities (2021) and platform trial participation (CAPTIVATE, 2025).
RemediumOne generates revenue primarily through professional-services contracts—quote-based, customized engagements—with global pharmaceutical sponsors (Takeda, Sanofi, Thermo Fisher, Sun Pharma, J&J, Lilly, Novartis, Gilead, GSK, Boehringer Ingelheim, Glenmark), major CROs (IQVIA, ICON, Parexel, Syneos), and academic institutions (The George Institute, University of Oxford, Imperial College, Duke-NUS, AIIMS, McMaster). Its go-to-market is enterprise field sales via direct partnership relationships, supplemented by thought-leadership channels including the trademarked biennial South Asia Forum and active conference participation. Pricing is not publicly disclosed and contracts are bespoke per engagement. Notable milestones include contributing 70% of global TRIDENT trial data from Sri Lanka (40% reduction in recurrent stroke risk), achieving 98%+ retention rates across trials, and conducting 40+ client/regulatory audits with zero major or critical findings.
Operationally, RemediumOne is positioned as a low-cost, high-quality South Asian alternative to Western CROs, leveraging Sri Lanka's free public healthcare infrastructure, treatment-naive patient populations, predictable regulatory timelines (16-18 weeks from application to FPI), and a non-communicable disease burden mirroring high-income countries. Strategic partnerships include the University of Kelaniya (founding), The George Institute for Global Health, Bill & Melinda Gates Foundation, Unitaid, and membership in the COGNITUM ARO Consortium (2023) and WHO Global Clinical Trial Forum (2025). The company is founder-led with no disclosed external PE/VC capital and remains in private ownership.
RemediumOne firmographics
Firmographics- Name
- RemediumOne
- Legal name
- RemediumOne Private Limited
- Website
- https://remediumone.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- RemediumOne is a Sri Lanka-based clinical development organization founded in 2009 that delivers end-to-end clinical trial management, medical affairs, and commercialization services to global pharmaceutical companies, CROs, and academic institutions through an 80+ site investigator network across 12+ therapeutic areas.
- Ownership category
- akta.pro rank
RemediumOne industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where RemediumOne is headquartered
LocationHeadquarters
- HQ city
- Colombo
- HQ country
- Sri Lanka
- HQ region
- Asia
Offices1 record
Markets served
RemediumOne business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Clinical Trial Management Services: Full-service clinical trial execution from protocol development through database lock, including site selection, patient recruitment and retention, monitoring, data management, and regulatory support
- Medical Affairs Services: Medical science liaison support, scientific publications, medical education, and advisory board facilitation services
- Commercialization Services: Market access strategy, pricing and reimbursement, health economics and outcomes research, and product launch planning and execution
- Consulting Services: Expert consulting spanning clinical trial design, project management, regulatory affairs, data management, market access, and health economics
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
RemediumOne product offering
Product offeringCore offering
RemediumOne is a clinical development organization providing end-to-end clinical trial management services in Sri Lanka for global pharmaceutical companies, CROs, and academic institutions. Core offerings span four pillars: Clinical Trials (full-service trial execution from feasibility through database lock, including site management, monitoring, data management, and regulatory support), Medical Affairs (scientific publications and medical education), Commercialisation (market access, pricing/reimbursement, and product launch planning), and Consulting (clinical trial design, regulatory affairs, and market access).
Product overview
RemediumOne is a clinical development organization offering an integrated suite of clinical research services centered around four core offerings: Clinical Trials (end-to-end trial management), Medical Affairs, Commercialisation, and Consulting. The Clinical Trials service serves as the primary offering, encompassing sub-services including Clinical Trial Monitoring, Phase II-IIIb Services, Clinical Trial Startup, Real World Evidence and Late Phase Trials, Drug Safety and Pharmacovigilance, Medical Writing and Communications, Biostatistics, Clinical Data Management, and Decentralised Solutions. The company operates across multiple therapeutic areas (Cardiovascular, CNS, Endocrine/Metabolic, Gastroenterology, Infectious Diseases/Vaccines, Nephrology, Oncology, Respiratory, Ophthalmology) and offers cross-functional solutions for Biosimilars and Rare Diseases. The portfolio is unified under a quality management system adhering to ISO and ICH-GCP standards, with services customizable to client needs from feasibility through database lock.
Differentiator
Problem solved
Functional benefit
Brands
- CTU - RemediumOne: Collaborative clinical research centre between Clinical Trials Unit (CTU) at University of Kelaniya and RemediumOne, recognized as the largest collaborative clinical research centre in Sri Lanka
- COGNITUM ARO Consortium
- South Asia Forum
- RemediumOne Global-Monitoring
Products and services
- Clinical Trials End-to-end clinical trial management services spanning site identification to database lock, including protocol development, site selection and management, patient recruitment and retention, data management, statistical analysis, and regulatory support for global pharmaceutical companies, CROs, and academic institutions.
- Medical Affairs
Quantifiable outcome
- 98%+ retention rate across trials, above industry average
- +5 more outcomes
Companies that use RemediumOne
Customer profileNamed customers18 records
Segments4 records
Ideal customer profiles4 records
RemediumOne technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RemediumOne partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered minor, core and major.
- Novaspire BiosciencesminorRecent MoU signing with Novaspire Biosciences for collaborative clinical development efforts.
- COGNITUM ARO ConsortiumcoreRemediumOne is a founding member of COGNITUM, an ARO (Academic Research Organisation) Consortium bringing together global leaders in scientific and clinical excellence to design and deliver clinical trials while fostering international partnerships.
- The George Institute for Global HealthcoreLong-standing collaboration with The George Institute for Global Health, led by Prof. Anushka Patel (CEO). The partnership has contributed to major global cardiovascular trials including TRIDENT, GMRx2, and COBRA-BPS. Prof. Patel serves on RemediumOne's International Advisory Panel and the organizations co-host the South Asia Forum.
- University of KelaniyacoreFounding partnership with the Clinical Trials Unit at the Faculty of Medicine, University of Kelaniya. This public-private partnership forms the foundation of RemediumOne's operations and has enabled Sri Lanka's contribution to landmark clinical trials. The CTU provides academic oversight and scientific leadership.
- Clinical Trial Service Unit, University of OxfordcoreInternational collaboration with Oxford's renowned clinical trials unit, contributing to the global evidence base for cardiovascular disease treatment and other therapeutic areas.
- Clinical Trials Unit, Imperial CollegemajorCollaboration with Imperial College London's clinical trials expertise for cardiovascular and other global health research projects.
- Duke Clinical Research InstitutemajorPartnership with Duke University's clinical research institute for exchange of expertise and collaborative research in cardiovascular and other therapeutic areas.
- Duke-NUS Graduate Medical SchoolmajorCollaboration with Duke-NUS in Singapore, co-hosting the South Asia Forum 2021 and contributing to regional clinical research capacity building.
- Stroke Centre, University of NottinghammajorInternational collaboration focused on stroke research and neurological clinical trials, contributing to global stroke prevention studies.
- Public Health Research Institute, McMaster UniversitymajorPartnership with McMaster University's public health research institute for collaborative research initiatives.
- All India Institute of Medical SciencesmajorCollaboration with AIIMS, India's premier medical research institution, for regional clinical research collaboration.
- University of Notre DamemajorPartnership with University of Notre Dame for the AEGIS spatial repellent project addressing dengue prevention in Sri Lanka.
- Bill & Melinda Gates FoundationcoreGlobal health foundation partnership for advancing clinical research in areas of unmet need, particularly in infectious diseases and public health.
- UnitaidcorePartnership with Unitaid funding for the AEGIS dengue spatial repellent project, providing resources for innovative vector-borne disease prevention research.
- Takeda PharmaceuticalsmajorPartnership with Takeda for vaccine trials including the DEN-301 dengue vaccine study. Sri Lanka was the second globally to reach enrollment targets of 2,100 subjects for Takeda.
- SanofimajorPartnership with Sanofi for immunology and inflammation clinical trials, with positive feedback on team performance and patient-centric approach.
- Sun PharmaceuticalsmajorPartnership with Sun Pharmaceuticals' Development Center of Excellence for Specialty Medicine, contributing to historical milestones in clinical development.
- Thermo Fisher ScientificmajorPartnership with Thermo Fisher Scientific's Early Development division for clinical trial execution in Sri Lanka, with positive feedback on study progress and communication.
- Metrics ResearchminorRemediumOne qualified as an Approved Vendor by Metrics Research, enabling engagement in their clinical trial projects.
- WHO Global Clinical Trial ForumcoreUniversity of Kelaniya became a member of the WHO Global Clinical Trial Forum network, expanding RemediumOne's international research network and recognition.
Scale indicators13 records
Recent moves12 records
Expansion highlights6 records
RemediumOne competitors and assessment
Company assessmentBroad incumbents
- ICON plc: ICON is a top-3 global CRO offering full-service clinical development across all phases and therapeutic areas. Comparable as both a RemediumOne client/partner and a global incumbent competing for the same pharma trial budgets across emerging markets.
- Syneos Health: Syneos Health is a global biopharmaceutical solutions provider combining clinical CRO services with commercialization. Comparable as a RemediumOne partner and a broad incumbent offering integrated clinical and commercialization services that overlap with RemediumOne's medical affairs and commercialization offerings.
- Parexel: Parexel is a major global CRO with deep therapeutic expertise across oncology, CNS, and rare disease. Comparable as a RemediumOne partner and a Tier-1 incumbent whose footprint across Asia-Pacific sets the standard for sponsor expectations.
- IQVIA: IQVIA is the world's largest CRO with comprehensive Phase I-IV clinical trial services globally. It is comparable as both a potential partner (current client of RemediumOne) and the dominant incumbent whose scale and geographic breadth define the competitive ceiling for regional CROs like RemediumOne.
Emerging players
- Clario: Clario is a clinical trial technology and endpoint solutions company supporting decentralized and hybrid trials. Comparable as an enabling participant in the clinical trial ecosystem, particularly relevant given RemediumOne's investment in decentralized clinical trial capabilities.
Direct peers
- Medpace: Medpace is a mid-sized full-service CRO with strong therapeutic specialization. Comparable as a peer operating in the same clinical development space with a similar focus on full-service trial execution, though Medpace operates globally while RemediumOne is regionally focused.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO focused on complex therapeutic areas including CNS and cardiometabolic. Comparable as a peer offering full-service clinical development with overlapping therapeutic area focus on cardiovascular and CNS, the two areas where RemediumOne has demonstrated landmark trial contributions.
- Veeda Clinical Research: Veeda Clinical Research is an India-based CRO offering clinical and bioanalytical services across Asia. Comparable as a South Asian regional peer with similar business model of providing cost-effective clinical trial execution for global pharma sponsors.
- Lambda Therapeutic Research: Lambda Therapeutic Research is an India-based CRO offering bioequivalence and clinical trial services across multiple therapeutic areas. Comparable as a South Asian regional CRO competing for emerging-market trial share with similar therapeutic breadth and Phase II-IV capabilities.
- Novotech: Novotech is an Asia-Pacific-focused CRO specializing in clinical trials across the region, with deep therapeutic expertise. It is the most direct peer to RemediumOne, competing for the same emerging-market trial share with a comparable regional specialization model, though at meaningfully larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
RemediumOne social profiles
Digital presenceRemediumOne compliance and trust
Trust signalCompliance3 records
RemediumOne financial estimates
Financial estimateRevenue estimate
Valuation estimate
RemediumOne leadership team
Management profileNumber of profiles
Profiles17 records
RemediumOne funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RemediumOne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RemediumOne
What does RemediumOne do?
RemediumOne is a clinical development organization providing end-to-end clinical trial management services in Sri Lanka for global pharmaceutical companies, CROs, and academic institutions. Core offerings span four pillars: Clinical Trials (full-service trial execution from feasibility through database lock, including site management, monitoring, data management, and regulatory support), Medical Affairs (scientific publications and medical education), Commercialisation (market access, pricing/reimbursement, and product launch planning), and Consulting (clinical trial design, regulatory affairs, and market access).
Is RemediumOne a public or private company?
RemediumOne is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RemediumOne founded?
RemediumOne was founded in 2009. It employs 51 to 100 people.
Where is RemediumOne based?
RemediumOne is headquartered in Colombo, Sri Lanka, in the Asia region.
How does RemediumOne make money?
Four revenue lines are on record. Clinical Trial Management Services are the primary driver. The others are medical Affairs Services, commercialization Services and consulting Services.
Who are RemediumOne's main competitors?
Broad incumbents on record are ICON plc, Syneos Health, Parexel and IQVIA. Clario is listed as an emerging player. Direct peers are Medpace, Worldwide Clinical Trials, Veeda Clinical Research, Lambda Therapeutic Research and Novotech.
Does RemediumOne have an API?
No public API is recorded for RemediumOne.
What industry is RemediumOne in?
RemediumOne's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 5417 and its SIC code is 8000.